EZTREK™
Novel DFU Treatment

• The Problem

• EZTREK™ Explained

• How EZTREK™ Works
The Problem: DFU

Patient Statistics

>1.75 Million patients in US are annually diagnosed with a DFU (6% of all diabetics)\(^1,2\)

Lifetime: 12% - 25% of diabetics will develop DFU\(^3\)

25% of DFUs never completely heal\(^2,3,4\)

40% Recurrence within 1 year after ulcer healing\(^4\)

50% Recurrence after 3 years\(^5\)

- Closure: 24% at 12 weeks\(^3\) / 30% at 20 weeks\(^3\)
- Unhealed: 70% unhealed after 20 weeks\(^6\)

46% of DFU Patients - Microvascular Complications\(^7\)

65% of DFU Patients - Macrovascular Complications\(^7\)

56% Become Infected\(^8\)

28% 3-Year mortality\(^9\) / 42% 5-year mortality\(^9\)

10% of Americans have diabetes and the number is increasing\(^10\)
- 34 million Americans
- 88 million American adults — approximately 1 in 3 have prediabetes

---

It is well documented that diabetic patients have impaired delta-6 desaturase (D6D) metabolic pathways from impaired insulin production. In particular, this metabolic defect causes a poor anti-inflammatory response in Type I patients. Even with insulin therapy, the pathway is still deficient. Type II patients also have significant impairment of D6D activity. Diabetic foot ulcer (DFU) wound healing is impaired.

This deficiency directly decreases PGE₁ output. Both a powerful anti-inflammatory and vasodilator, PGE₁, is critical to expedited DFU healing. Diabetic patients may possess only 42% of PGE₁’s binding functionality — a 58% decrease compared with normal, non-diabetic patients. Steroids (glucocorticoids) further impair the Δ-6 desaturase pathway. During hypoglycemic episodes, the hormone glucagon is produced, further impeding the Δ-6 desaturase pathway (by means of cAMP).

Compensating for impaired Δ-6 desaturase deficiency, the new medicament EZTREK™ — uniquely addresses underlying etiology — and simultaneously optimizes multiple metabolic pathways:

1. The Δ-6 desaturase metabolic pathway favors the omega-3 series. Alpha-linolenic acid is important for tissue structure and support. However, PGE₁ is produced exclusively from the omega-6 series. EZTREK™ solves this issue by specific calibration of both omega-6 / -3 series and with specific modulation of their long-chain metabolites.

2. EZTREK™ further enhances patients’ production of PGE₁ by calibration of gamma-linolenic acid with docosahexaenoic acid.

3. Diabetic patients frequently consume (processed) foods that decrease the most fundamental substrate precursor of PGE₁ — functional linoleic acid. Furthermore, the important cellular unfolded protein response (UPR) in secretory cells, such as the pancreas, is activated not only by unfolded proteins, but also by aberrant lipid composition (induced by the diet) of the ER membrane referred to as lipid bilayer stress. This response can trigger long-term stress (inflammation) in cells. EZTREK™ calibrated EFA / eicosanoid modulating ratios are formulated to compensate for this and other obstacles that may impede the Δ-6 desaturase pathway.

4. Fibroblasts in the dermis — important in allowing skin to regenerate connective tissue to recover from injury and maintain the extracellular matrix — are not maximized with Δ-6 desaturase deficiency.

With continued EZTREK™ use, both acute and chronic DFUs heal faster.

How EZTREK™ Works
Uniquely Treating DFU

Utilizing Novel Mechanisms of Action

Lipids are the #1 (Modifiable) Variable in Tissue Composition with Potential to Impact Healing.\(^1,2\)

**Eicosanoid Optimization**

**Omega-3 family**

- α-linolenic acid 18:3 ω-3
- Stearidonic acid 18:4 ω-3
- Eicosatetraenoic acid 20:4 ω-3
- Eicosapentaenoic acid EPA 20:5 ω-3
  - Sprecher’s Shunt
  - Increases PGE₁ & TXA₁
  - Decreases TXA₂ & LTB₄
  - Δ6 desaturase
  - Δ5 desaturase

**Omega-6 family**

- Linoleic acid 18:2 ω-6
- γ-linolenic acid GLA 18:3 ω-6
- Dihomo γ-linolenic acid DGLA 20:3 ω-6
- Arachidonic acid AA 20:4 ω-6
- Docosapentaenoic acid DPA 22:5 ω-6
- Docosatetraenoic acid 22:4 ω-6
- Docosahexaenoic acid DHA 22:6 ω-3

**EZTREK™**, the new patented Medical Food — specifically and uniquely formulated for the DFU population. Positively impacts multiple metabolic pathways simultaneously. **EZTREK™** distinctively compensates for impaired Δ-6 desaturase functionality — increasing PGE₁ output to expedite DFU wound healing.

*With continued use, faster healing of both acute and chronic DFUs will occur.*
Metabolic Pathways Required For Optimal Wound Healing


